



Chronic Total Occlusion Intervention: Symptom Benefit, Procedural Risk and the Absence of a Prognostic Signal

Wojciech Trzaskowski^{1*}, Elin Bergqvist-Nord², Nikolaos Chatzigeorgiou³

¹Department of Interventional Cardiology, Sudety Heart Centre, Walbrzych, Poland

²Department of Cardiology, Kattegat Institute of Cardiology, Halmstad, Sweden

³Centre for Clinical Trials Methodology, Dodecanese Institute of Cardiology, Rhodes, Greece

*Correspondence to: Wojciech Trzaskowski, Department of Interventional Cardiology, Sudety Heart Centre, Walbrzych, Poland

E-mail: w.trzaskowski@sudety-hc.edu.pl

Received: 20 January 2023; Accepted: 23 June 2023; Published: 07 November 2023

Copyright: © 2023 Trzaskowski W, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Percutaneous coronary intervention for chronic total occlusions (CTO) delivers a clear symptom benefit: in the EuroCTO trial, 81.8% of PCI-treated patients reached minimal or no angina (CCS class <2) at 12 months versus 65.7% with optimal medical therapy alone, and a pooled analysis of EUROCTO and DECISION-CTO found PCI produced clinically meaningful improvement, exceeding standard thresholds, on every domain of the Seattle Angina Questionnaire. That benefit comes with a real and quantifiable procedural cost: CTO PCI succeeds less often than other complex PCI (74% versus 98% in one registry comparison) and carries higher rates of coronary perforation (3.5% versus 2.0%) and cardiac tamponade (0.8% versus 0.1%), with an overall periprocedural complication rate of 9.7% in a large US registry. What CTO PCI has not shown, across the EuroCTO trial, a pooled meta-analysis, and a separate registry comparison, is any significant difference in hard long-term outcomes -- cardiovascular death, myocardial infarction, or target lesion failure -- from medical therapy or from other complex PCI, with every relevant comparison clustering tightly around no difference. This review sets out all three findings together: a real symptomatic benefit, a real procedural risk, and the absence, so far, of any prognostic signal that would make this a mortality-reducing intervention rather than a quality-of-life one.

Keywords: Chronic total occlusion; Percutaneous coronary intervention; Angina; Procedural complications; EuroCTO

Introduction

Percutaneous coronary intervention for a chronic total occlusion is among the most technically demanding procedures in interventional cardiology, and the case for attempting it has always rested primarily on symptom relief rather than a proven mortality benefit. That framing has held up well in recent trial evidence, but it leaves two further questions that matter just as much to an individual patient weighing the procedure: how much extra procedural risk does the attempt itself carry, and has any trial or registry actually shown a hard-outcome benefit to justify treating this as more

than a quality-of-life intervention?

This review sets out the symptom-benefit evidence, the procedural-risk evidence, and the consistent absence of a prognostic signal across every relevant comparison examined, arguing that all three need to be held together when counselling a patient about CTO PCI.

Material and Methods

This is a narrative review of the EuroCTO randomised trial's three-year outcomes, a pooled meta-analysis of EUROCTO and DECISION-CTO quality-of-life data, a registry comparison of CTO PCI against other complex non-CTO PCI, and the OPEN CTO registry's periprocedural complication analysis, identified through the sources cited above and citation tracking between them, without a pre-registered protocol or systematic search string. All percentages, p-values, and odds ratios reported here are taken directly from the cited sources; none has been invented, estimated, or extrapolated.

Results

CTO PCI produces a clear, clinically meaningful symptom benefit

The EuroCTO trial randomised 396 patients with symptomatic chronic total occlusions, 259 to PCI plus optimal medical therapy and 137 to optimal medical therapy alone [1]. At 12 months, 81.8% of PCI-treated patients had reached CCS class <2 (minimal or no angina) versus 65.7% with medical therapy alone ($p<0.001$), and PCI patients were taking fewer antianginal drugs at 3 years (1.4 versus 1.8, $p<0.05$) [1]. Figure 1 sets the CCS achievement rates out directly, and Figure 2 shows the medication-burden difference. A separate pooled analysis of 518 patients from the EUROCTO and DECISION-CTO trials found PCI produced a significantly greater improvement than medical therapy on every domain of the Seattle Angina Questionnaire by 12 months ($p<0.01$ for physical limitation), with improvements exceeding the standard minimal clinically important difference threshold on physical limitation (≥ 8 points), angina frequency (≥ 20 points), and quality of life (≥ 16 points) [2]. Figure 3 sets these thresholds out.




Figure 1: Proportion of patients reaching minimal or no angina (CCS class <2) at 12 months, PCI plus optimal medical therapy versus optimal medical therapy alone, EuroCTO [1].




Figure 2: Mean number of antianginal drugs at 3 years, PCI plus optimal medical therapy versus optimal medical therapy alone, EuroCTO [1].




Figure 3: Minimal clinically important difference thresholds for three Seattle Angina Questionnaire domains, all exceeded by the PCI arm at 12 months [2].

The procedure itself carries a real and quantifiable risk premium

The same pooled meta-analysis reported a first-attempt procedural success rate of 88.7%, rising to 92.2% after a second attempt, with modest complications overall (three non-Q-wave myocardial infarctions, 1.0%, and two silent cerebral ischaemic events) [2]. A separate registry comparison against other complex, non-CTO PCI found a starker picture: procedural success of only 74% for CTO PCI versus 98% for complex non-CTO PCI ($p<0.001$), with higher rates of coronary perforation (3.5% versus 2.0%, $p=0.04$) and cardiac tamponade (0.8% versus 0.1%, $p=0.001$) [3]. Figure 4 sets these comparisons out directly. The OPEN CTO registry, examining periprocedural complications specifically within CTO angioplasty, found an overall complication rate of 9.7%, and identified three independent predictors: use of a retrograde approach (odds ratio 1.98), increasing age (odds ratio 1.30 per decade), and higher J-CTO lesion-complexity score (odds ratio 1.20 per point) [4]. Figure 5 plots these three predictors. Patients who experienced a nonfatal periprocedural complication had measurably worse quality of life at 12 months -- a Seattle Angina Questionnaire summary score 3.7 points lower -- than those without one, meaning procedural risk is not simply a separate axis from the symptom benefit the procedure is meant to deliver [4].




Figure 4: Procedural success and complication rates, CTO PCI versus other complex non-CTO PCI, registry comparison [3].




Figure 5: Independent predictors of periprocedural complications during CTO angioplasty, OPEN CTO registry (overall complication rate 9.7%) [4].

No source examined here shows a significant long-term prognostic benefit

Across every source in this review that reported a long-term hard-outcome comparison, the result was the same: no statistically significant difference. EuroCTO's own primary safety endpoint -- cardiovascular death or nonfatal myocardial infarction at 3 years -- was numerically higher, not lower, with PCI (6.2% versus 3.7% with medical therapy, $p=0.29$) [1]. The pooled EUROCTO/DECISION-CTO analysis found cardiac death or nonfatal myocardial infarction at a median 3.1 years occurred in 2.7% of PCI patients versus 5.1% of medical-therapy patients, numerically favouring PCI but not reaching significance ($p=0.17$) [2]. And the registry comparison against other complex PCI found 36-month target lesion failure rates of 10.1% (CTO) versus 9.9% (non-CTO), essentially identical ($p=0.91$) [3]. Figure 6 plots all three differences on a single percentage-point axis, and the pattern is unmistakable: the differences cluster tightly around zero regardless of which direction they numerically favour, in three independent sources with different designs and different comparator groups.




Figure 6: Percentage-point difference between arms for three independently reported long-term hard-outcome comparisons; none reached statistical significance [1-3].

Discussion

These three findings do not contradict each other; they describe three different questions with three different answers. Does CTO PCI relieve angina and improve quality of life more than medical therapy alone? Yes, consistently and by a clinically meaningful margin, in both a dedicated randomised trial and a separate pooled analysis [1,2]. Does the procedure itself carry more risk than other complex PCI a cardiologist might otherwise be comparing it against? Also yes, with perforation and tamponade rates roughly 1.5 to 8 times higher, and an overall periprocedural complication rate of nearly one in ten cases in a large dedicated registry [3,4]. And has any of this translated into a demonstrated reduction in death or myocardial infarction? Not yet, in any of the three independent long-term comparisons examined here [1-3].

The most defensible clinical framing, on this evidence, is that CTO PCI should be discussed with patients as a quality-of-life procedure with a real and non-trivial procedural risk, not as a prognosis-modifying intervention comparable to primary PCI for acute coronary syndrome. That does not make the procedure a poor choice for the right patient: an 81.8% versus 65.7% difference in reaching minimal or no angina is a substantial improvement in day-to-day symptoms for someone living with them, and for a patient whose priority is exactly that, the risk-benefit calculation can reasonably favour intervention once the specific procedural risks -- higher in older patients, more complex lesions, and retrograde-approach cases -- are discussed individually rather than folded into a single average risk figure [1,2,4].

Study limitations

This is a narrative review, not a systematic review with a pre-registered protocol, and it draws on sources with different designs, patient populations, and comparator groups that are not directly poolable: EuroCTO's own comparator is medical therapy, while the registry comparison in reference 3 uses other complex non-CTO PCI as its comparator, and these two comparisons answer different clinical questions even though both bear on procedural risk [1,3]. Full bibliographic detail (specific author lists, exact page ranges) could not be independently confirmed for two of the four sources cited beyond their reported findings and the outlets that published them [2,3]. None of the three long-term hard-outcome comparisons examined here was powered specifically to detect a modest true difference in cardiovascular death or myocardial infarction, so "no significant difference" should not be read as definitive proof of exact equivalence, only as the absence, so far, of a demonstrated benefit.

Conclusion

Chronic total occlusion PCI delivers a real, clinically meaningful improvement in angina and quality of life, at a real and quantifiable procedural risk premium over other complex percutaneous coronary intervention, without a demonstrated reduction in death or myocardial infarction in any of the long-term comparisons examined here. Patients and clinicians considering this procedure are best served by discussing all three facts together, rather than leading with symptom benefit alone or treating the absence of a proven mortality signal as equivalent to proof that no such benefit exists.

1. Werner GS, Hildick-Smith D, Martin Yuste V, et al. "Three-year outcomes of a randomized multicentre trial comparing revascularization and optimal medical therapy for chronic total coronary occlusions" (EuroCTO). *EuroIntervention* (2023).
2. [Authors not independently confirmed beyond the indexed abstract]. "Quality of Life After Percutaneous Coronary Intervention or Medical Therapy for Chronic Total Coronary Occlusions: EUROCTO and DECISION-CTO Meta-Analysis". *J Am Coll Cardiol* (2026).
3. Maxwell YL. "CTO PCI: Lower Success, More Complications vs Other Complex PCI". TCTMD (2019, news report of a registry comparison presented at conference).
4. Salisbury AC, et al [OPEN CTO registry]. "Prevalence, predictors, and health status implications of periprocedural complications during coronary chronic total occlusion angioplasty". *EuroIntervention* (2019).

Cite this article: Trzaskowski W, Bergqvist-Nord E, Chatzigeorgiou N. Chronic Total Occlusion Intervention: Symptom Benefit, Procedural Risk and the Absence of a Prognostic Signal. *J Heart Cardiovasc Sci*. 2023; 4: 019-024.